Ipamorelin

Ipamorelin 

Product Details

Overview

Ipamorelin is a synthetic pentapeptide belonging to the class of growth hormone secretagogues (GHSs). Pharmacologically, it acts as an agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), i.e. the ghrelin receptor, and its defining feature is selective stimulation of growth hormone (GH) secretion. In the scientific literature, ipamorelin is often described as the first selective GH secretagogue, because compared with older GHRPs it shows greater hormonal selectivity and less stimulation of ACTH and cortisol (PubMed).

What it is and how it works

After binding to GHS-R1a, ipamorelin activates signaling pathways that trigger endogenous GH release from pituitary somatotroph cells. This receptor belongs to the broader ghrelin system, which is involved not only in GH-axis regulation but also in metabolism, energy balance, and neuroendocrine physiology. Mechanistically, ipamorelin is therefore not growth hormone itself, but rather a growth hormone secretagogue—a compound that stimulates the body’s own hormonal release (PubMed). Unlike less selective peptides such as GHRP-2 or GHRP-6, ipamorelin was characterized in preclinical pharmacology by the finding that, at GH-effective doses, it did not significantly stimulate ACTH or cortisol. This feature established its scientific profile as a more selective tool for studying the GH axis with less spillover into hypothalamic-pituitary-adrenal signaling (PubMed).

Effects confirmed by research

The best documented effect of ipamorelin is stimulation of growth hormone secretion. In the foundational pharmacology study, ipamorelin was described as a potent and selective GHS-R1a agonist that elicited GH responses comparable to older GHRPs, but with greater specificity for GH release. This selectivity is important because it allows investigators to study GH signaling with less endocrine confounding from other hormonal axes (PubMed). In human pharmacokinetic-pharmacodynamic studies in healthy volunteers, ipamorelin produced dose-dependent increases in GH, supporting its research value as a controllable GH secretagogue. These studies mainly focused on the relationship between dose, plasma concentrations, and GH response amplitude (PubMed). Preclinical studies also suggested that ipamorelin may support bone growth and anabolic processes mediated through GH signaling. In animal experiments, increases in longitudinal bone growth and changes in body weight were observed, although these findings should be interpreted strictly as preclinical data rather than direct clinical evidence in humans (PubMed).

Broader biological context

It is important to emphasize that GHS-R1a is not restricted to GH signaling alone. It is part of a receptor system closely linked to ghrelin biology and therefore to food intake, metabolism, energy expenditure, and behavioral regulation. Although ipamorelin is more selective than older GHRPs, it still belongs to a biological class with broader physiological relevance than growth hormone alone. For that reason, it is scientifically more accurate to describe it as a selective modulator of the GH axis within the ghrelin system, rather than simply a “muscle-growth peptide” (PubMed).

Professional scientific description

From a scientific standpoint, Ipamorelin is a selective GHS-R1a agonist whose main research-supported characteristic is stimulation of endogenous GH secretion with a lower tendency to co-stimulate ACTH and cortisol compared with classical GHRPs. Its research relevance lies in enabling analysis of GH-secretagogue signaling with greater receptor and hormonal selectivity. This makes it an important tool in studies of somatotropic regulation, ghrelin biology, and the pharmacodynamics of GH secretagogues (PubMed). For scientific or educational content, the three most accurate pillars are: selective stimulation of endogenous GH via GHS-R1a, lower impact on ACTH/cortisol compared with older GHRPs, research relevance in GH-axis physiology, ghrelin signaling, and endocrine pharmacology (PubMed).

References

Raun, K., et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. Gobburu, J. V. S., et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999. Johansen, P. B., et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999. Veldhuis, J. D., Bowers, C. Y. Integrating GHS into the ghrelin system. Endocrine Reviews. 2010. Albarrán-Zeckler, R. G., Smith, R. G. The ghrelin receptors (GHS-R1a and GHS-R1b). Endocrine Development / receptor review. 2013. Moulin, A., et al. Recent developments in ghrelin receptor ligands. Molecular and Cellular Endocrinology. 2007. Abizaid, A., Hougland, J. L. Ghrelin Signaling: GOAT and GHS-R1a. Trends in Endocrinology and Metabolism. 2020.